Oncology

Cellectis successfully bags USD 164 million for Gene-editing and CAR-T programs After a rough journey in 2017, the road seems clear for French CAR-T specialist Cellectis, which has recently closed a USD 164 million U.S. public offering. Out of total funding amount around USD 100 million will be used to build commercial infrastructure including a manufacturing plant for its CAR-T candidates. It uses donated cells rather than cells harvested from individual patients. Alexion to takeover Wilson Therapeutics for USD 855 million Alexion has signed a deal worth USD 855 million to acquire Wilson Therapeutics. The takeover will provide Alexion control over WTX101, a phase 3 tr...